FDA Approves Ranluspec (ranibizumab-hkdz), an Interchangeable Biosimilar to Lucentis

BLA FilingapprovedRanluspecLucentisPositive

AI Analysis

Summary

The FDA approved Lupin Limited's Ranluspec (ranibizumab-hkdz) as an interchangeable biosimilar to Lucentis. This is a significant regulatory approval for a biosimilar product in the ophthalmology market.

Outcome Details

FDA approved Ranluspec (ranibizumab-hkdz) as an interchangeable biosimilar to Lucentis

Importance:8/10

Sentiment:

0.85

biosimilarFDA approvalinterchangeableranibizumabLupin

Related Companies

$GMRE-PA $UTHR

Read the original article

Published by Drugs.com New Drug Approvals on June 5, 2026 10:06 PM

Read Original